4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

      1 , 2 , 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 11 , 28 , 11 , 28 , 31 , 32 , 28 , 1 , 1
      JAMA
      American Medical Association (AMA)

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d2245281e617">Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment for patients with HFrEF, even those without diabetes. </p>

          Related collections

          Author and article information

          Journal
          JAMA
          JAMA
          American Medical Association (AMA)
          0098-7484
          March 27 2020
          Affiliations
          [1 ]British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
          [2 ]Division of Cardiac Surgery, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
          [3 ]Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut
          [4 ]Department of Cardiology, University of Minnesota, Minneapolis
          [5 ]Second Department of Internal Medicine, Cardiovascular Medicine, General Teaching Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
          [6 ]Department of Medicine, Saarland University Hospital, Homburg/Saar, Germany
          [7 ]Division of Cardiology, Taipei Veterans General Hospital, Taipei, Taiwan
          [8 ]National Yang-Ming University, Taipei, Taiwan
          [9 ]Department of Cardiology, Medanta, Gurgaon, Haryana, India
          [10 ]Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
          [11 ]Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
          [12 ]Division of Cardiology, Instituto Cardiovascular de Buenos Aires, Buenos Aires, Argentina
          [13 ]Department Cardiology, Medical University of Lodz, Lodz, Poland
          [14 ]Fifth Department of Internal Medicine, Comenius University in Bratislava, Bratislava, Slovakia
          [15 ]Shanghai Institute of Cardiovascular Disease, Department of Cardiology, Zhongshan Hospital Fudan University, Shanghai, China
          [16 ]Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
          [17 ]Clinic of Cardiology, National Cardiology Hospital, Sofia, Bulgaria
          [18 ]Cardiovascular Division of Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan
          [19 ]Institute of Medicine, Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
          [20 ]Heart and Vascular Center, Semmelweis University, Budapest, Hungary
          [21 ]Instituto do Coracao (InCor), Hospital das Clínicas Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
          [22 ]Department of Cardiology, Montreal Heart Institute, Montreal, Ontario, Canada
          [23 ]Department of Internal Medicine, Tan Tao University, Tan Duc, Vietnam
          [24 ]Department of Cardiology, Gentofte University Hospital Copenhagen, Copenhagen, Denmark
          [25 ]Department of Myocardial Disease and Heart Failure, National Medical Research Center of Cardiology, Moscow, Russia
          [26 ]Department of Cardiology Copenhagen University Hospital, Copenhagen, Denmark
          [27 ]St Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City
          [28 ]Late Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
          [29 ]Universidad Nacional de Córdoba, Córdoba, Argentina
          [30 ]Center for Heart Diseases, University Hospital, Wroclaw Medical University, Wroclaw, Poland
          [31 ]Early Discovery and Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
          [32 ]Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland
          Article
          10.1001/jama.2020.1906
          7157181
          32219386
          529a67d1-98ff-4783-8507-e0ba5877f730
          © 2020
          History

          Comments

          Comment on this article